{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:53:17Z","timestamp":1777614797250,"version":"3.51.4"},"reference-count":26,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T00:00:00Z","timestamp":1562284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"publisher","award":["CH\/11\/2\/28733"],"award-info":[{"award-number":["CH\/11\/2\/28733"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EU FP7","award":["IAPP 324325"],"award-info":[{"award-number":["IAPP 324325"]}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/L027933\/1"],"award-info":[{"award-number":["BB\/L027933\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Human adenovirus 5 (HAdV-5) is used as a vector in gene therapy clinical trials, hence its interactions with the host immune system have been widely studied. Previous studies have demonstrated that HAdV-5 binds specifically to murine coagulation factor X (mFX), inhibiting IgM and complement-mediated neutralization. Here, we examined the physical binding of immune components to HAdV-5 by nanoparticle tracking analysis, neutralization assays, mass spectrometry analysis and in vivo experiments. We observed that purified mouse Immunoglobulin M (IgM) antibodies bound to HAdV-5 only in the presence of complement components. Active serum components were demonstrated to bind to HAdV-5 in the presence or absence of mFX, indicating that immune molecules and mFX might bind to different sites. Since binding of mFX to HAdV-5 blocks the neutralization cascade, these findings suggested that not all complement-binding sites may be involved in virion neutralization. Furthermore, the data obtained from serum neutralization experiments suggested that immune molecules other than IgM and IgG may trigger activation of the complement cascade in vitro. In vivo experiments were conducted in immunocompetent C57BL\/6 or immuno-deficient Rag2-\/- mice. HAdV-5T* (a mutant HAdV-5 unable to bind to human or mFX) was neutralized to some extent in both mouse models, suggesting that murine immunoglobulins were not required for neutralization of HAdV-5 in vivo. Liquid Chromatography-Mass Spectrometry (LC-MS\/MS) analysis of HAdV-5 and HAdV-5T* after exposure to murine sera showed stable binding of C3 and C4b in the absence of mFX. In summary, these results suggest that HAdV-5 neutralization can be mediated by both the classical and alternative pathways and that, in the absence of immunoglobulins, the complement cascade can be activated by direct binding of C3 to the virion.<\/jats:p>","DOI":"10.3390\/v11070616","type":"journal-article","created":{"date-parts":[[2019,7,5]],"date-time":"2019-07-05T11:44:16Z","timestamp":1562327056000},"page":"616","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Human Adenovirus Serotype 5 Is Sensitive to IgM-Independent Neutralization In Vitro and In Vivo"],"prefix":"10.3390","volume":"11","author":[{"given":"Andor","family":"Doszpoly","sequence":"first","affiliation":[{"name":"Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"de la Cuesta","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrella","family":"Lopez-Gordo","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"B\u00e9n\u00e9zech","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9691-6210","authenticated-orcid":false,"given":"Stuart A.","family":"Nicklin","sequence":"additional","affiliation":[{"name":"Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow G12 8TA, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5576","authenticated-orcid":false,"given":"Andrew H.","family":"Baker","sequence":"additional","affiliation":[{"name":"Centre for Cardiovascular Science, Queen\u2019s Medical Research Institute, University of Edinburgh, Edinburgh EH16 4TJ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,7,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1517\/17425247.2014.938637","article-title":"The importance of coagulation factors binding to adenovirus: Historical perspectives and implications for gene delivery","volume":"11","author":"Denby","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"4426","DOI":"10.1128\/JCM.43.9.4426-4433.2005","article-title":"Detection of antibodies against adenovirus protein ix, fiber, and hexon in human sera by immunoblot assay","volume":"43","author":"Bauer","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1089\/hum.2015.019","article-title":"Efficient transduction of primary vascular cells by the rare adenovirus serotype 49 vector","volume":"26","author":"Dakin","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1089\/10430349950018364","article-title":"Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo","volume":"10","author":"Muruve","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1089\/10430340152712665","article-title":"Toxicity of a first-generation adenoviral vector in rhesus macaques","volume":"13","author":"Lozier","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/10430340152712692","article-title":"Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons","volume":"13","author":"Morral","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/sj.cgt.7700870","article-title":"Biological activities of a recombinant adenovirus p53 (sch 58500) administered by hepatic arterial infusion in a phase 1 colorectal cancer trial","volume":"13","author":"Atencio","year":"2006","journal-title":"Cancer Gene Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood-2009-03-208835","article-title":"Identification of coagulation factor (f)x binding sites on the adenovirus serotype 5 hexon: Effect of mutagenesis on fx interactions and gene transfer","volume":"114","author":"Alba","year":"2009","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/JVI.79.12.7478-7491.2005","article-title":"Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity","volume":"79","author":"Shayakhmetov","year":"2005","journal-title":"J. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Bradshaw, A.C., Parker, A.L., Duffy, M.R., Coughlan, L., van Rooijen, N., K\u00e4h\u00e4ri, V.M., Nicklin, S.A., and Baker, A.H. (2010). Requirements for receptor engagement during infection by adenovirus complexed with blood coagulation factor x. PLoS Pathog., 6.","DOI":"10.1371\/journal.ppat.1001142"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nm.3107","article-title":"Coagulation factor x shields adenovirus type 5 from attack by natural antibodies and complement","volume":"19","author":"Xu","year":"2013","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Ma, J., Duffy, M.R., Deng, L., Dakin, R.S., Uil, T., Custers, J., Kelly, S.M., McVey, J.H., Nicklin, S.A., and Baker, A.H. (2015). Manipulating adenovirus hexon hypervariable loops dictates immune neutralisation and coagulation factor x-dependent cell interaction in vitro and in vivo. PLoS Pathog., 11.","DOI":"10.1371\/journal.ppat.1004673"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2009-12-260026","article-title":"Biodistribution and retargeting of fx-binding ablated adenovirus serotype 5 vectors","volume":"116","author":"Alba","year":"2010","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/gt.2016.32","article-title":"The relevance of coagulation factor x protection of adenoviruses in human sera","volume":"23","author":"Duffy","year":"2016","journal-title":"Gene Ther."},{"key":"ref_15","first-page":"271","article-title":"Simple methods for preparing recombinant adenoviruses for high-efficiency transduction of vascular cells","volume":"30","author":"Nicklin","year":"1999","journal-title":"Methods Mol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","article-title":"Multiple vitamin k-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes","volume":"108","author":"Parker","year":"2006","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"15553","DOI":"10.18632\/oncotarget.14948","article-title":"Kalirin and chd7: Novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1074\/mcp.M113.031591","article-title":"Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed maxlfq","volume":"13","author":"Cox","year":"2014","journal-title":"Mol. Cell. Proteom."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"17361","DOI":"10.1021\/bi981177x","article-title":"Coagulation factor x-binding protein from deinagkistrodon acutus venom is a gla domain-binding protein","volume":"37","author":"Atoda","year":"1998","journal-title":"Biochemistry"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.4049\/jimmunol.160.10.4776","article-title":"Enhanced b-1 cell development, but impaired igg antibody responses in mice deficient in secreted igm","volume":"160","author":"Boes","year":"1998","journal-title":"J. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e02487-16","DOI":"10.1128\/JVI.02487-16","article-title":"Defining a novel role for the coxsackievirus and adenovirus receptor in human adenovirus serotype 5 transduction","volume":"91","author":"Doszpoly","year":"2017","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1002\/eji.1830201205","article-title":"A mechanism of activation of the alternative complement pathway by the classical pathway: Protection of c3b from inactivation by covalent attachment to c4b","volume":"20","author":"Meri","year":"1990","journal-title":"Eur. J. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0065-2776(08)04004-2","article-title":"The amplification loop of the complement pathways","volume":"104","author":"Lachmann","year":"2009","journal-title":"Adv. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.chom.2019.02.016","article-title":"Complement c4 prevents viral infection through capsid inactivation","volume":"25","author":"Bottermann","year":"2019","journal-title":"Cell Host Microbe"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Bhushan, B. (2012). Nanoparticle tracking analysis. Encyclopedia of Nanotechnology, Springer.","DOI":"10.1007\/978-90-481-9751-4"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Harmon, A.W., Moitra, R., Xu, Z., and Byrnes, A.P. (2018). Hexons from adenovirus serotypes 5 and 48 differentially protect adenovirus vectors from neutralization by mouse and human serum. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0192353"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/7\/616\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:02:55Z","timestamp":1760187775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/7\/616"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,5]]},"references-count":26,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7]]}},"alternative-id":["v11070616"],"URL":"https:\/\/doi.org\/10.3390\/v11070616","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,5]]}}}